Cohance Lifesciences Peer Comparison

Snapshot Summary

Cohance Lifesciences Ltd. demonstrates strong profitability with a substantial ROE, but its high PE ratio indicates it may be overvalued compared to peers. However, it has the lowest debt levels, making it a safer investment compared to others with higher debt ratios. Among its peers, Dr. Reddy's Laboratories stands out for its strong profitability and low valuation metrics, making it a potential value pick.

• Cohance Lifesciences has the lowest debt to equity ratio (0.0465), indicating low financial risk.
• Dr. Reddy's Laboratories offers strong profitability with a PE ratio of 15.50, making it a highly attractive value pick.
• Mankind Pharma shows the highest revenue growth YoY (18.12%) and 3-Year (155.25%), indicating excellent growth potential.

• Dr. Reddy's Laboratories Ltd.: Strong profitability metrics with high ROE and low valuation, making it a solid investment.
• Mankind Pharma Ltd.: Exceptional growth trajectory with the highest revenue growth and strong profitability.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
COHANCE	₹742.85	₹28,426.65Cr	111.05	14.20%	18.44%	0.05
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Cohance Lifesciences Peer Comparison

Snapshot Summary